SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007
12 references·3 citing·38 second hop
Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)Global Spending on Orphan Drugs in France…Why rare diseases are an important medical and social issue (2008)Why rare diseases are an impo…Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada (2008)Guidelines for Conducting Pha…Does orphan drug legislation really answer the needs of patients? (2008)Does orphan drug legislation …Assessing the economic challenges posed by orphan drugs (2007)Assessing the economic challe…Rare diseases and orphan drugs (2006)Rare diseases and orphan drugsOrphan drug development is progressing too slowly (2006)Orphan drug development is pr…Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases (2006)Adopting Orphan Drugs — Two D…A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)A journey of hope: lessons le…Orphan drugs and the NHS: should we value rarity? (2005)Orphan drugs and the NHS: sho…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Orphan drugs: legal aspects, current situation (2002)Orphan drugs: legal aspects, …Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Cost-Effectiveness Analysis a…Unintended effects of orphan product designation for rare neurological diseases (2012)Unintended effects of orphan …Drugs for Rare Diseases: Influence of Orphan Designation Status on Price (2011)Drugs for Rare Diseases: Infl…Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe (2010)Issues Surrounding Orphan Dis…Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)International society for pharmacoeconomics and outcomes research (2006)Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis (2007)Budget impact analysis in economic evaluation: a proposal for a clearer definition (2011)Health economic consequences of reducing salt intake and replacing saturated fat with polyunsaturated fat in the adult Finnish population: estimates based on the FINRISK and FINDIET studies (2011)A Methodological Review of US Budget-Impact Models for New Drugs (2016)QALYfying the value of life. (1987)Explaining the Identifiable Victim Effect (1997)A rational framework for decision making by the National Institute For Clinical Excellence (NICE) (2002)Public healthcare resource allocation and the Rule of Rescue (2008)SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE‐BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS‐SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN (2012)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Delivering affordable cancer care in high-income countries (2011)Drugs for exceptionally rare diseases: do they deserve special status for funding? (2005)Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs? (2017)Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group (2018)Economics of coronary artery bypass grafting. (1985)Setting Health Care Priorities in Oregon (1991)One Thousand Health-Related Quality-of-Life Estimates (2000)Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES (2003)Pricing and reimbursement of orphan drugs: the need for more transparency (2011)Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (2015)Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years (2010)The supportive care needs of parents with a child with a rare disease: results of an online survey (2016)Alone in a Crowd? Parents of Children with Rare Diseases’ Experiences of Navigating the Healthcare System (2018)Drug development for orphan diseases in the context of personalized medicine (2009)Translation of rare disease research into orphan drug development: disease matters (2009)Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry (2016)Incentives for orphan drug research and development in the United States (2008)Policies and Incentives for Promoting Innovation in Antibiotic Research (2010)Exploring emerging technologies using metaphors – A study of orphan drugs and pharmacogenomics (2008)Orphan drugs: the regulatory environment (2012)
this work references cited by second hop

References

  • 2004National Institute for Clinical Excellence and its value judgments767 cited
  • 2008Why rare diseases are an important medical and social issue621 cited
  • 2001Cost-Effectiveness Analysis and the Consistency of Decision Making431 cited
  • 2007Assessing the economic challenges posed by orphan drugs279 cited
  • 2005Orphan drugs and the NHS: should we value rarity?229 cited
  • 2006A journey of hope: lessons learned from studies on rare diseases and orphan drugs185 cited
  • 2006Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases162 cited
  • 2006Rare diseases and orphan drugs144 cited
  • 2008Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada80 cited
  • 2008Does orphan drug legislation really answer the needs of patients?79 cited
  • 2002Orphan drugs: legal aspects, current situation79 cited
  • 2006Orphan drug development is progressing too slowly70 cited

Cited by

  • 2010Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe51 cited
  • 2011Drugs for Rare Diseases: Influence of Orphan Designation Status on Price51 cited
  • 2012Unintended effects of orphan product designation for rare neurological diseases

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

49 cited